Evidence map›Paper›PMID 36384901›Full record

ReviewInternal medicine (Tokyo, Japan)2023

Paraganglioma with High Levels of Dopamine, Dopa Decarboxylase Suppression, Dopamine β-hydroxylase Upregulation and Intra-tumoral Melanin Accumulation: A Case Report with a Literature Review.

Masahiro Nezu, Yosuke Hirotsu, Kenji Amemiya, Toru Tateno, Soichi Takizawa, Masaharu Inoue, Hitoshi Mochizuki, Kyoko Hosaka, Constance Chik, Toshio Oyama and 1 more

Open access · diamondAbstract readReviewCase Reports
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Masahiro NezuDepartment of Endocrinology and Diabetes, Yamanashi Central Hospital, Japan.
Yosuke HirotsuGenome Analysis Center, Yamanashi Central Hospital, Japan.
Kenji AmemiyaGenome Analysis Center, Yamanashi Central Hospital, Japan.
Toru TatenoDivision of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Canada.
Soichi TakizawaDepartment of Endocrinology and Diabetes, Yamanashi Central Hospital, Japan.
Masaharu InoueDepartment of Endocrinology and Diabetes, Yamanashi Central Hospital, Japan.
Hitoshi MochizukiGenome Analysis Center, Yamanashi Central Hospital, Japan.
Kyoko HosakaDepartment of Urology, Yamanashi Central Hospital, Japan.
Constance ChikDivision of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Canada.
Toshio OyamaDepartment of Pathology, Yamanashi Central Hospital, Japan.
Masao OmataGenome Analysis Center, Yamanashi Central Hospital, Japan.
Yamanashi Prefectural Central Hospital · JPUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Object Exclusively dopamine-producing pheochromocytoma/paraganglioma (PPGL) is an extremely rare subtype. In this condition, intratumoral dopamine β-hydroxylase (DBH), which controls the conversion of norepinephrine from dopamine, is impaired, resulting in suppressed norepinephrine and epinephrine production. However, the rarity of this type of PPGL hampers the understanding of its pathophysiology. We therefore conducted genetic and immunohistological analyses of a patient with an exclusively dopamine-producing paraganglioma. Methods Paraganglioma samples from a 52-year-old woman who presented with a 29.6- and 41.5-fold increase in plasma and 24-h urinary dopamine, respectively, but only a minor elevation in the plasma norepinephrine level was subjected to immunohistological and gene expression analyses of catecholamine synthases. Three tumors carrying known somatic PPGL-related gene variants (HRAS, EPAS1) were used as controls. Whole-exome sequencing (WES) was also performed using the patient's blood and tumor tissue. Results Surprisingly, the protein expression of DBH was not suppressed, and its mRNA expression was clearly higher in the patient than in the controls. Furthermore, dopa decarboxylase (DDC), which governs the conversion of 3,4-dihydroxyphenyl-

Indexed as

Adrenal Gland NeoplasmsParagangliomaPheochromocytomaDNA-Binding ProteinsDopa DecarboxylaseDopamineDopamine beta-HydroxylaseFemaleHumansLevodopaMelaninsMiddle AgedNorepinephrineRNA-Binding ProteinsUp-RegulationCSDE1 protein, humanDNA-Binding ProteinsDopa DecarboxylaseDopamineDopamine beta-HydroxylaseLevodopaMelaninsNorepinephrineRNA-Binding Proteins3,4-dihydroxyphenyl-L-alanine (L-DOPA)catecholamine synthasedopaminedopamine decarboxylasePheochromocytoma and paraganglioma

Identifiers

PMID36384901
PMCPMC10372287
OpenAlexW4309246899

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.